Patent Oppositions in metabolic drugs industry

Explore the competitive field of metabolic drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in metabolic drugs technology and learn how to protect your intellectual property.

Get Patent Opposition Report for metabolic drugs

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Report

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Last updated on: Oct 2, 2025
CompanyTotal Oppositions
NOVARTIS174
BOEHRINGER INGELHEIM93
NOVO NORDISK73
AMGEN41
NUTRICIA41
BRISTOL MYERS SQUIBB37
CELGENE35
NESTLE32
PFIZER29
F HOFFMANN LA ROCHE28

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the metabolic drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the metabolic drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Oct 2, 2025
Patent NumberTitleApplicantOpposition DateOpposition Name

Get alerts on new patent oppositions in the metabolic drugs industry

Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKAug 27, 2025DR REDDYS LABORATORIES
Preparation Containing Tetracyclic Compound At High DoseCHUGAI SEIYAKU KABUSHIKI KAISHAAug 20, 2025MANSKE
Preparation Containing Tetracyclic Compound At High DoseCHUGAI SEIYAKU KABUSHIKI KAISHAAug 19, 2025TEVA PHARMACEUTICALS
Composition Comprising Epa, Ma And Leucine For Improving Muscle FunctionNUTRICIAAug 13, 2025FRESENIUS KABI DEUTSCHLAND
Processes For Preparing Jak Inhibitors And Related Intermediate CompoundsINCYTEAug 12, 2025KARO
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKAug 10, 2025ADALVO
Treatment Of Prostate CancerMYOVANT SCIENCESAug 7, 2025ABG LAW
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKAug 7, 2025GENERICS UK
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKAug 6, 2025WUESTHOFF & WUESTHOFF
Methods Of Making Chimeric Antigen Receptor -Expressing CellsNOVARTISAug 1, 2025STRAWMAN

To stay ahead in the competitive metabolic drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the metabolic drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleApplicantTotal Oppositions
Oct 12, 2022S1P Receptor Modulators For Treating Multiple SclerosisNOVARTIS23
Apr 14, 2021Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGY22
Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM18
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofCELGENE15
Mar 10, 2021Novel Antitumoral Use Of CabazitaxelSANOFI13
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA11
Aug 18, 2021Formulations Of EnzalutamideMEDIVATION PROSTATE THERAPEUTICS11
Mar 2, 2022Modified Nucleoside, Nucleotide, And Nucleic Acid CompositionsMODERNA10
Sep 14, 2022Therapeutic Uses Of EmpagliflozinBOEHRINGER INGELHEIM10
Aug 21, 2019Rapamycin Derivative For Treating Pancreas CancerNOVARTIS10